Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Free Cash Flow (2019 - 2023)

Alx Oncology Holdings' Free Cash Flow history spans 5 years, with the latest figure at -$39.8 million for Q4 2023.

  • For Q4 2023, Free Cash Flow fell 87.69% year-over-year to -$39.8 million; the TTM value through Dec 2023 reached -$131.6 million, down 45.22%, while the annual FY2025 figure was -$84.4 million, 31.06% up from the prior year.
  • Free Cash Flow for Q4 2023 was -$39.8 million at Alx Oncology Holdings, down from -$29.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.8 million in Q4 2019 and bottomed at -$39.8 million in Q4 2023.
  • The 5-year median for Free Cash Flow is -$19.2 million (2021), against an average of -$18.6 million.
  • The largest annual shift saw Free Cash Flow plummeted 384.57% in 2020 before it surged 42.69% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at -$2.8 million in 2019, then crashed by 384.57% to -$13.6 million in 2020, then crashed by 30.26% to -$17.7 million in 2021, then decreased by 19.55% to -$21.2 million in 2022, then crashed by 87.69% to -$39.8 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Free Cash Flow are -$39.8 million (Q4 2023), -$29.9 million (Q3 2023), and -$33.4 million (Q2 2023).